Effect Of Unani formulation with massage in Diabetic nerve pain

Comparative evaluation of Dalk-i-Muâ??tadil with Roghan-i-Qust versus Roghan-i-Sosan in Distal Symmetric Polyneuropathy (DSPN) of Diabetic originâ??A randomised clinical trial - DNM

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/04/041831

Enrollment

Registered

2022-04-12

Start date

Unknown

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E134- Other specified diabetes mellituswith neurological complications

Interventions

Intervention1: Dalk-i- Muâ??tadil with Roghan-i-Qust: Qust Talkh, Sumbul-ut-Teeb, 90 gm each Jund bedastar, Filfil Siyah, Farfiyun, Miya-e-Saila, 30gm each Roghan-i-zaitoon 500 gm Mode of applicatio

Eligibility

Inclusion criteria

Inclusion criteria: Documented Diagnosed cases of Type 1 or 2 diabetes Patients of either sex Patients older than 20 years and less than 60 years of age Stable glycemic control for 3 months i.e. HbA1c DSPN defined by: Bilateral reduced or absent reflexes at the ankles Bilateral impaired vibration, pinprick, fine touch or temperature perception in the distal lower extremities. Persistent distal burning or dull pain in the feet Persistent proximal aching pain in the legs Paroxysmal electric, shooting, stabbing pain Dysasthesias

Exclusion criteria

Exclusion criteria: Patient less than 20 years and more than 60 years Physiological state as pregnancy and lactation. Patients having abnormal blood urea, serum creatinine, SGOT, SGPT. Other causes of neuropathy or lower extremity pain Uncontrolled hypertension at screen (sitting systolic >160 mmHg and/or sitting diastolic >90 mmHg Currently participating in another clinical study in which the subject is, or will be exposed to an investigational or non-investigational drug or device. Pathological state such as cardiovascular diseases, renal diseases, hepatic diseases, peripheral arterial diseases. Unwillingness or inability to comply the requirements of the protocol

Design outcomes

Primary

Measure	Time frame
change in â?¢ Vibration perception threshold â?¢ Michigan neuropathy screening instrument â?¢ Chronic Acquired Polyneuropathy Patient-Reported Index (CAPPRI) scales Timepoint: 30 days	—

Secondary

Measure	Time frame
NilTimepoint: Nil	—

Countries

India

Contacts

Public ContactDr Hamid Ali

Dept of Ilaj bit tadbeer National Institute of Unani Medicine Kottigepalya Bangalore

dr.hamidali4u@gmail.com7975301806

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026